A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Pancreatic Cancer
Public ClinicalTrials.gov record NCT02231723. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase Ib Clinical Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Metastatic Pancreatic Adenocarcinoma
Study identification
- NCT ID
- NCT02231723
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 1
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Enrollment
- 139 participants
Conditions and interventions
Conditions
Interventions
- BBI608 Drug
- Nab-paclitaxel Drug
- Gemcitabine Drug
- Oxaliplatin Drug
- Leucovorin Drug
- Irinotecan Drug
- Fluorouracil Drug
- MM-398 Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 31, 2014
- Primary completion
- May 31, 2020
- Completion
- May 31, 2020
- Last update posted
- Nov 17, 2023
2014 – 2020
United States locations
- U.S. sites
- 12
- U.S. states
- 8
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic Arizona | Phoenix | Arizona | 85054 | — |
| Emory University Winship Cancer Institute | Atlanta | Georgia | 30322 | — |
| Parkview Research Center | Fort Wayne | Indiana | 46845 | — |
| Indiana University Health Goshen Center for Cancer Care | Goshen | Indiana | 46526 | — |
| Indiana University Melvin and Bren Simon Cancer Center | Indianapolis | Indiana | 46202 | — |
| Comprehensive Cancer Centers of Nevada | Henderson | Nevada | 89014 | — |
| The Ohio State University Comprehensive Cancer Center | Columbus | Ohio | 43210 | — |
| The University of Tennessee Medical Center | Knoxville | Tennessee | 37920 | — |
| Texas Oncology - Austin Midtown | Austin | Texas | 78705 | — |
| Texas Oncology - Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology - SAT&BC | San Antonio | Texas | 78216 | — |
| Virginia Oncology Associates | Norfolk | Virginia | 23502 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT02231723, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 17, 2023 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT02231723 live on ClinicalTrials.gov.